Form 8-K

• Total revenue of $17.6 million in Q4 2025, down 4% YoY
• Gross profit margin of 81.2% in Q4 2025
• Net loss of $11.6 million in Q4 2025, or $0.38 per share
• Full year 2025 revenue of $71.6 million, up 11% YoY

AVITA Medical reported its financial results for the fourth quarter and full year ended December 31, 2025. Total revenue in Q4 2025 was $17.6 million, down 4% from $18.4 million in the prior year period, primarily due to lingering reimbursement headwinds. Gross profit margin was 81.2%, reflecting product mix and inventory-related adjustments. Net loss in Q4 2025 was $11.6 million, or $0.38 per share, flat compared to the prior year period. For the full year 2025, total revenue increased 11% to $71.6 million, within the company's revised guidance. Gross profit margin was 82.1% for the year. Net loss for the full year 2025 was $48.6 million, or $1.74 per share, an improvement from a net loss of $61.8 million, or $2.39 per share, in the prior year. The company also announced the refinancing of its existing debt under a new $60 million credit facility with Perceptive Advisors, which will strengthen its capital structure and support long-term growth. Looking ahead, AVITA Medical provided full year 2026 revenue guidance in the range of $80 to $85 million, representing growth of 12% to 19% compared to 2025.

Full year 2026 revenue expected in the range of $80 to $85 million, representing growth of approximately 12% to 19% compared to 2025 revenue.

AVITA Medical remains focused on disciplined cash management, sharpening execution, and accelerating commercial momentum across its core U.S. burn and trauma center opportunity.